NL-OMON21233已完成不适用
Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration.
Prof. Dr. R.O. SchlingemannDepartment of Ophthalmology, Room A2-122Academisch Medisch CentrumMeibergdreef 91105 AZ AmsterdamTel +31205663616e-mail: r.schlingemann@amc.uva.nl0 个研究点目标入组 306 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 306
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients 60 years of age or higher;
- •2. Patients with primary or recurrent sub-, juxta- or extrafoveal CNV secondary to AMD, including those with RAP, that may benefit from anti-VEGF treatment in the opinion of the investigator;
排除标准
- •1. Ocular treatment with anti-angiogenic drugs in the last 2 months or Triamcinolone in the last 6 months;
- •2. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline;
研究者
相似试验
尚未招募
不适用
BRVO.macular edema secondary to a retinal vein occlusionNL-OMON23545Academic Medical Center (AMC)Department of Ophthalmology296
已完成
3 期
Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusionsMacular edema secondary to a retinal vein occlusion10047060NL-OMON46979Academisch Medisch Centrum228
已完成
3 期
Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edemadiabetic macular edema10047060NL-OMON47349Academisch Medisch Centrum126
Unknown
2 期
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)Retinal Vein OcclusionNCT01635803Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)296
Unknown
2 期
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)Diabetic Macular EdemaNCT01635790Prof. dr. R.O. Schlingemann246